Tris Pharma intros Onyda XR

Tris, a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder, pain, addiction and neurological disorders, is offering Onyda XR (clonidine hydrochloride) extended-release oral suspension. 

The Food and Drug Administration approved the once-a-day liquid medication with nighttime dosing in May 2024 for the treatment of ADHD as a monotherapy or as an adjunctive therapy to approved central nervous system stimulant medications in pediatric patients six years and older.

“Non-stimulant ADHD therapies are an increasingly important option for patients who do not respond adequately to stimulant medications or experience negative side effects from them,” said Manesh Naidu, chief commercial officer at Tris Pharma. “As ADHD Awareness Month kicks off, we’re especially pleased that Onyda XR is now available to patients in the United States who might benefit from it as the first-and-only liquid non-stimulant ADHD medication. We look forward to expanding access to this treatment and making a meaningful difference in the lives of those living with ADHD.”

[Read more: Tris Pharma acquires FDA OK for Dyanavel]

Onyda XR was developed using Tris Pharma’s drug-delivery technology to enable a once-a-day extended-release profile, and with its liquid formulation, patients now have an option that allows for easier administration in a range of doses. Onyda XR is a liquid non-stimulant ADHD medication approved in the United States and the only approved non-stimulant ADHD medication with nighttime dosing.

“As the prevalence of ADHD continues to grow, so does the need for the availability of a wider variety of treatment options that meet the unique and individual needs of patients,” said Rakesh Jain, clinical professor at Texas Tech University School of Medicine – Permian Basin. “Until now, there has not been an extended-release oral suspension non-stimulant option available to people with ADHD who may struggle taking pills or require a longer-acting therapy. The availability of Onyda XR represents a meaningful advancement in tailoring treatment to the diverse needs of people with ADHD, and I am excited to now have this important additional medicine available for my patients.”

[Read more: Tris Pharma taps Anthony Amato to lead generics business development]